ABMD:NSD-Abiomed Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 349.41

Change

-1.65 (-0.47)%

Market Cap

USD 15.93B

Volume

0.16M

Avg Analyst Target

USD 370.00 (+5.89%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-19 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

-0.86 (-0.14%)

USD47.10B 67.84 46.35
PODD Insulet Corporation

+8.02 (+2.75%)

USD20.10B 2,208.27 254.01
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+0.27 (+0.35%)

USD11.71B 49.94 26.26
TNDM Tandem Diabetes Care Inc

+4.30 (+3.50%)

USD7.74B 1,191.84 251.84
SWAV ShockWave Medical Inc

+0.26 (+0.13%)

USD6.80B N/A N/A
INMD InMode Ltd

-0.25 (-0.29%)

USD6.37B 55.77 39.02
IART Integra LifeSciences Holdings ..

+1.03 (+1.52%)

USD5.72B 28.03 18.47
LIVN LivaNova PLC

+0.21 (+0.25%)

USD4.38B 77.40 N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing ABMD

Symbol Name Weight Mer Price(Change) Market Cap
CHEP AGFiQ U.S. Market Neutral.. 0.00 % 1.42 %

N/A

USD0.75M
MOM AGFiQ U.S. Market Neutral.. 0.00 % 2.58 %

N/A

USD4.73M
SLIM The Obesity ETF 0.00 % 0.35 %

N/A

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.78% 49% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.78% 49% F 51% F
Trailing 12 Months  
Capital Gain 25.90% 49% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.90% 49% F 51% F
Trailing 5 Years  
Capital Gain 178.93% 78% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 178.93% 78% C+ 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 43.63% 69% D+ 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.63% 69% D+ 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 71.31% 45% F 24% F
Risk Adjusted Return 61.18% 81% B- 77% C+
Market Capitalization 15.93B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 103.80 22% F 11% F
Price/Book Ratio 11.53 20% F 11% F
Price / Cash Flow Ratio 58.02 14% F 8% F
EV/EBITDA 50.66 35% F 16% F
Management Effectiveness  
Return on Equity 12.82% 89% B+ 76% C
Return on Invested Capital 13.93% 89% B+ 84% B
Return on Assets 12.24% 98% A+ 95% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.36 47% F 35% F
Short Percent 1.86% 77% C+ 62% D-
Beta 1.35 43% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.